Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on
Abstract
:1. Malignant Pleural Mesothelioma
2. Osteopontin
3. Mesothelin
4. Fibulin-3
5. HMGB1 (High Mobility Group Box 1)
6. Aquaporin-1
7. Perspective: Protein & Molecular Biomarkers?
Author Contributions
Funding
Conflicts of Interest
References
- Robinson, B.W.S.; Lake, R.A. Advances in malignant mesothelioma. N. Engl. J. Med. 2005, 353, 1591–1603. [Google Scholar] [CrossRef] [PubMed]
- Robinson, B.W.S.; Musk, A.W.; Lake, R.A. Malignant mesothelioma. Lancet 2005, 366, 397–408. [Google Scholar] [CrossRef]
- Abakay, O.; Tanrikulu, A.C.; Palanci, Y.; Abakay, A. The value of inflammatory parameters in the prognosis of malignant mesothelioma. J. Int. Med. Res. 2014, 42, 554–565. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Frank, A.L.; Joshi, T.K. The global spread of asbestos. Ann. Glob. Health 2014, 80, 257–262. [Google Scholar] [CrossRef] [PubMed]
- Spirtas, R.; Heineman, E.F.; Bernstein, L.; Beebe, G.W.; Keehn, R.J.; Stark, A.; Harlow, B.L.; Benichou, J. Malignant mesothelioma: Attributable risk of asbestos exposure. Occup. Environ. Med. 1994, 51, 804–811. [Google Scholar] [CrossRef] [PubMed]
- Mao, W.; Zhang, X.; Guo, Z.; Gao, Z.; Pass, H.I.; Yang, H.; Carbone, M. Association of asbestos exposure with malignant mesothelioma incidence in eastern China. JAMA Oncol. 2017, 3, 562–564. [Google Scholar] [CrossRef] [PubMed]
- Kazan-Allen, L. Asbestos and mesothelioma: Worldwide trends. Lung Cancer 2005, 49 (Suppl. 1), S3–S8. [Google Scholar] [CrossRef] [PubMed]
- Ramael, M.; Nagels, J.; Heylen, H.; De Schepper, S.; Paulussen, J.; De Maeyer, M.; van Haesendonck, C. Detection of SV40 like viral DNA and viral antigens in malignant pleural mesothelioma. Eur. Respir. J. 1999, 14, 1381–1386. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Galateau-Salle, F.; Bidet, P.; Iwatsubo, Y.; Gennetay, E.; Renier, A.; Letourneux, M.; Pairon, J.C.; Moritz, S.; Brochard, P.; Jaurand, M.C.; et al. SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma, and non-malignant pulmonary diseases. J. Pathol. 1998, 184, 252–257. [Google Scholar] [CrossRef]
- Weiner, S.J.; Neragi-Miandoab, S. Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. J. Cancer Res. Clin. Oncol. 2009, 135, 15–27. [Google Scholar] [CrossRef] [PubMed]
- Van Gelder, T.; Damhuis, R.A.M.; Hoogsteden, H.C. Prognostic factors and survival in malignant pleural mesothelioma. Eur. Respir. J. 1994, 7, 1035–1038. [Google Scholar] [PubMed]
- Bianchi, C.; Brollo, A.; Ramani, L.; Zuch, C. Pleural plaques as risk indicators for malignant pleural mesothelioma: A necropsy-based study. Am. J. Ind. Med. 1997, 32, 445–449. [Google Scholar] [CrossRef]
- Komurcuoglu, B.; Cirak, A.K.; Kirakli, S.C.; Polat, G.; Yucel, N.; Usluer, O.; Erer, O.; Balci, G.; Gayaf, M.; Guldaval, F.; et al. Prognostic factors affecting survival in malignant pleural mesothelioma: Analysis of 125 subjects. Tumori 2014, 100, 55–59. [Google Scholar] [CrossRef] [PubMed]
- De Perrot, M.; McRae, K.; Anraku, M.; Karkouti, K.; Waddell, T.K.; Pierre, A.F.; Darling, G.; Keshavjee, S.; Johnston, M.R. Risk Factors for Major Complications after Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma. Ann. Thorac. Surg. 2008, 85, 1206–1210. [Google Scholar] [CrossRef] [PubMed]
- Ledda, C.; Loreto, C.; Bracci, M.; Mangano, D.; Migliore, M.; Ricceri, V.; Musumeci, A.; Costa, C.; Pomara, C.; Rapisarda, V. High risk of pleural plaques and parenchymal abnormalities in women living in biancavilla (Italy). Future Oncol. 2016, 12, 63–65. [Google Scholar] [CrossRef] [PubMed]
- Ledda, C.; Pomara, C.; Bracci, M.; Mangano, D.; Ricceri, V.; Musumeci, A.; Ferrante, M.; Musumeci, G.; Loreto, C.; Fenga, C.; et al. Natural carcinogenic fiber and pleural plaques assessment in a general population: A cross-sectional study. Environ. Res. 2016, 150, 23–29. [Google Scholar] [CrossRef] [PubMed]
- Zeren, E.H.; Gümürdülü, D.; Roggli, V.L.; Tuncer, I.; Zorludemir, S.; Erkisi, M. Environmental malignant mesothelioma in Southern Anatolia: A study of fifty cases. Environ. Health Perspect. 2000, 108, 1047–1050. [Google Scholar] [CrossRef] [PubMed]
- Rapisarda, V.; Ledda, C.; Ricceri, V.; Arena, F.; Musumeci, A.; Marconi, A.; Fago, L.; Bracci, M.; Santarelli, L.; Ferrante, M. Detection of pleural plaques in workers exposed to inhalation of natural fluoro-edenite fibres. Oncol. Lett. 2015, 9, 2046–2052. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Ledda, C.; Loreto, C.; Pomara, C.; Rapisarda, G.; Fiore, M.; Ferrante, M.; Bracci, M.; Santarelli, L.; Fenga, C.; Rapisarda, V. Sheep lymph-nodes as a biological indicator of environmental exposure to fluoro-edenite. Environ. Res. 2016, 147, 97–101. [Google Scholar] [CrossRef] [PubMed]
- Ledda, C.; Loreto, C.; Matera, S.; Massimino, N.; Cannizzaro, E.; Musumeci, A.; Migliore, M.; Fenga, C.; Pomara, C.; Rapisarda, V. Early effects of fluoro-edenite: Correlation between IL-18 serum levels and pleural and parenchymal abnormalities. Future Oncol. 2016, 12, 59–62. [Google Scholar] [CrossRef] [PubMed]
- Ledda, C.; Caltabiano, R.; Loreto, C.; Cinà, D.; Senia, P.; Musumeci, A.; Ricceri, V.; Pomara, C.; Rapisarda, V. Prevalence of anti-nuclear autoantibodies in subjects exposed to natural asbestiform fibers: A cross-sectional study. J. Immunotoxicol. 2018, 15, 24–28. [Google Scholar] [CrossRef] [PubMed]
- Ledda, C.; Costa, C.; Matera, S.; Puglisi, B.; Costanzo, V.; Bracci, M.; Fenga, C.; Rapisarda, V.; Loreto, C. Immunomodulatory effects in workers exposed to naturally occurring asbestos fibers. Mol. Med. Rep. 2017, 15, 3372–3378. [Google Scholar] [CrossRef] [PubMed]
- Gianfagna, A.; Ballirano, P.; Bellatreccia, F.; Bruni, B.; Paoletti, E.; Oberti, R. Characterization of amphibole fibers linked to mesothelioma in the area of Biancavilla, Eastern Sicily, Italy. Mineral. Mag. 2003, 67, 1221–1229. [Google Scholar] [CrossRef]
- Baumann, F.; Maurizot, P.; Mangeas, M.; Ambrosi, J.; Douwes, J.; Robineau, B. Pleural mesothelioma in New Caledonia: Associations with environmental risk factors. Environ. Health Perspect. 2011, 119, 695–700. [Google Scholar] [CrossRef] [PubMed]
- Constantopoulos, S.H. Environmental mesothelioma associated with tremolite asbestos: Lessons from the experiences of Turkey, Greece, Corsica, New Caledonia and Cyprus. Regul. Toxicol. Pharmacol. 2008, 52 (Suppl. 1), S110–S115. [Google Scholar] [CrossRef] [PubMed]
- Luce, D.; Bugel, I.; Goldberg, P.; Goldberg, M.; Salomon, C.; Billon-Galland, M.; Nicolau, J.; Quénel, P.; Fevotte, J.; Brochard, P. Environmental exposure to tremolite and respiratory cancer in New Caledonia: A case-control study. Am. J. Epidemiol. 2000, 151, 259–265. [Google Scholar] [CrossRef] [PubMed]
- Mutsaers, S.E.; Prêle, C.M.; Pengelly, S.; Herrick, S.E. Mesothelial cells and peritoneal homeostasis. Fertil. Steril. 2016, 106, 1018–1024. [Google Scholar] [CrossRef] [PubMed]
- Yamamoto, T.; Nagasue, K.; Okuno, S.; Yamakawa, T. The role of peritoneal lavage and the prognostic significance of mesothelial cell area in preventing encapsulating peritoneal sclerosis. Peritoneal. Dial. Int. 2010, 30, 343–352. [Google Scholar] [CrossRef] [PubMed]
- Maeda, M.; Yamamoto, S.; Chen, Y.; Kumagai-Takei, N.; Hayashi, H.; Matsuzaki, H.; Lee, S.; Hatayama, T.; Miyahara, N.; Katoh, M.; et al. Resistance to asbestos-induced apoptosis with continuous exposure to crocidolite on a human T cell. Sci. Total Environ. 2012, 429, 174–182. [Google Scholar] [CrossRef] [PubMed]
- Kumagai-Takei, N.; Nishimura, Y.; Maeda, M.; Hayashi, H.; Matsuzaki, H.; Lee, S.; Hiratsuka, J.; Otsuki, T. Effect of asbestos exposure on differentiation of cytotoxic t lymphocytes in mixed lymphocyte reaction of human peripheral blood mononuclear cells. Am. J. Respir. Cell Mol. Biol. 2013, 49, 28–36. [Google Scholar] [CrossRef] [PubMed]
- Yang, H.; Testa, J.R.; Carbone, M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr. Treat. Options Oncol. 2008, 9, 147–157. [Google Scholar] [CrossRef] [PubMed]
- Loreto, C.; Rapisarda, V.; Carnazza, M.L.; Musumeci, G.; Valentino, M.; Fenga, C.; Martinez, G. Fluoro-edenite fibres induce lung cell apoptosis: An in vivostudy. Histol. Histopathol. 2008, 23, 319–326. [Google Scholar] [PubMed]
- Martinez, G.; Loreto, C.; Rapisarda, V.; Masumeci, G.; Valentino, M.; Carnazza, M.L. Effects of exposure to fluoro-edenite fibre pollution on the respiratory system: An in vivo model. Histol. Histopathol. 2006, 21, 595–601. [Google Scholar] [PubMed]
- Franklin, P.; Alfonso, H.; Reid, A.; Olsen, N.; Shilkin, K.B.; Brims, F.; de Klerk, N.; Musk, A.W. Asbestos exposure and histological subtype of malignant mesothelioma. Occup. Environ. Med. 2016, 73, 749–752. [Google Scholar] [CrossRef] [PubMed]
- Brčić, L.; Jakopović, M.; Brčić, I.; Klarić, V.; Milošević, M.; Šepac, A.; Samaržija, M.; Seiwerth, S. Reproducibility of histological subtyping of malignant pleural mesothelioma. Virchows Arch. 2014, 465, 679–685. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Kao, S.C.; Yan, T.D.; Lee, K.; Burn, J.; Henderson, D.W.; Klebe, S.; Kennedy, C.; Vardy, J.; Clarke, S.; van Zandwijk, N.; et al. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J. Thorac. Oncol. 2011, 6, 602–605. [Google Scholar] [CrossRef] [PubMed]
- Monaco, S.; Mehrad, M.; Dacic, S. Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples. Adv. Anat. Pathol. 2018, 25, 24–30. [Google Scholar] [CrossRef] [PubMed]
- Ak, G.; Tada, Y.; Shimada, H.; Metintas, S.; Ito, M.; Hiroshima, K.; Masatoshi, T.; Muzaffer, M. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin. BMC Cancer 2017, 17, 212. [Google Scholar] [CrossRef] [PubMed]
- Cigognetti, M.; Lonardi, S.; Fisogni, S.; Balzarini, P.; Pellegrini, V.; Tironi, A.; Bercich, L.; Bugatti, M.; Rossi, G.; Murer, B. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod. Pathol. 2015, 28, 1043–1057. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Takeda, M.; Kasai, T.; Enomoto, Y.; Takano, M.; Morita, K.; Kadota, E.; Iizuka, N.; Maruyama, H.; Nonomura, A. Genomic gains and losses in malignant mesothelioma demonstrated by FISH analysis of paraffin-embedded tissues. J. Clin. Pathol. 2012, 65, 77–82. [Google Scholar] [CrossRef] [PubMed]
- Creaney, J.; Robinson, B.W.S. Serum and pleural fluid biomarkers for mesothelioma. Curr. Opin. Pulm. Med. 2009, 15, 366–370. [Google Scholar] [CrossRef] [PubMed]
- Arnold, D.T.; Maskell, N.A. Biomarkers in mesothelioma. Ann. Clin. Biochem. 2018, 55, 49–58. [Google Scholar] [CrossRef] [PubMed]
- Scherpereel, A.; Lee, Y.C.G. Biomarkers for mesothelioma. Curr. Opin. Pulm. Med. 2007, 13, 339–343. [Google Scholar] [CrossRef] [PubMed]
- Takeuchi, S.; Seike, M.; Noro, R.; Soeno, C.; Sugano, T.; Zou, F.; Uesaka, H.; Nishijima, N.; Matsumoto, M.; Minegishi, Y. Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed. Int. J. Oncol. 2014, 45, 1886–1894. [Google Scholar] [CrossRef] [PubMed]
- Pass, H.I.; Lott, D.; Lonardo, F.; Harbut, M.; Liu, Z.; Tang, N.; Carbone, M.; Webb, C.; Wali, A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl. J. Med. 2005, 353, 1564–1573. [Google Scholar] [CrossRef] [PubMed]
- Hu, Z.D.; Liu, X.F.; Liu, X.C.; Ding, C.M.; Hu, C.J. Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: A systematic review and meta-analysis. Clin. Chim. Acta 2014, 433, 44–48. [Google Scholar] [CrossRef] [PubMed]
- Ohashi, R.; Tajima, K.; Takahashi, F.; Cui, R.; Gu, T.; Shimizu, K.; Nishio, K.; Fukuoka, K.; Nakano, T.; Takahashi, K. Osteopontin modulates malignant pleural mesothelioma cell functions in vitro. Anticancer Res. 2009, 29, 2205–2214. [Google Scholar] [CrossRef] [PubMed]
- Grigoriu, B.; Scherpereel, A.; Devos, P.; Chahine, B.; Letourneux, M.; Lebailly, P.; Grégoire, M.; Porte, H.; Copin, M.C.; Lassalle, P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 2007, 13, 2928–2935. [Google Scholar] [CrossRef] [PubMed]
- Cappia, S.; Righi, L.; Mirabelli, D.; Ceppi, P.; Bacillo, E.; Ardissone, F.; Molinaro, L.; Scagliotti, G.V.; Papotti, M. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am. J. Clin. Pathol. 2008, 130, 58–64. [Google Scholar] [CrossRef] [PubMed]
- Paleari, L.; Rotolo, N.; Imperatori, A.; Puzone, R.; Sessa, F.; Franzi, F.; Meacci, E.; Camplese, P.; Cesario, A.; Paganuzzi, M. Osteopontin is not a specific marker in malignant pleural mesothelioma. Int. J. Biol. Markers 2009, 24, 112–117. [Google Scholar] [CrossRef] [PubMed]
- Creaney, J.; Robinson, B.W.S. Detection of malignant mesothelioma in asbestos-exposed individuals: The potential role of soluble mesothelin-related protein. Hematol. Oncol. Clin. N. Am. 2005, 19, 1025–1040. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Qiu, S.; Zhang, Y.; Merino, M.; Fetsch, P.; Avital, I.; Filie, A.; Pastan, I.; Hassan, R. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Res. 2012, 32, 5151–5158. [Google Scholar] [PubMed]
- Ho, M.; Hassan, R.; Zhang, J.; Wang, Q.; Onda, M.; Bera, T.; Pastan, I. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin. Cancer Res. 2005, 11, 3814–3820. [Google Scholar] [CrossRef] [PubMed]
- Tian, L.; Zeng, R.; Wang, X.; Shen, C.; Lai, Y.; Wang, M.; Che, G. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: A meta-analysis. Oncotarget 2017, 8, 46425–46435. [Google Scholar] [CrossRef] [PubMed]
- Hollevoet, K.; Nackaerts, K.; Thimpont, J.; Germonpré, P.; Bosquée, L.; de Vuyst, P.; Legrand, C.; Kellen, E.; Kishi, Y.; Delanghe, J.R.; et al. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am. J. Respir. Crit. Care Med. 2010, 181, 620–625. [Google Scholar] [CrossRef] [PubMed]
- Grigoriu, B.; Chahine, B.; Zerimech, F.; Grégoire, M.; Balduyck, M.; Copin, M.; Devos, P.; Lassalle, P.; Scherpereel, A. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin. Biochem. 2009, 42, 1046–1050. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Franko, A.; Dolzan, V.; Kovac, V.; Arneric, N.; Dodic-Fikfak, M. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma. Dis. Markers 2012, 32, 123–131. [Google Scholar] [CrossRef] [PubMed]
- Filiberti, R.; Marroni, P.; Spigno, F.; Merlo, D.F.; Mortara, V.; Caruso, P.; Cioè, A.; Michelazzi, L.; Bruzzone, A.; Bobbio, B. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos. Oncology 2014, 86, 33–43. [Google Scholar] [CrossRef] [PubMed]
- Schneider, J.; Hoffmann, H.; Dienemann, H.; Herth, F.J.F.; Meister, M.; Muley, T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J. Thorac. Oncol. 2008, 3, 1317–1324. [Google Scholar] [CrossRef] [PubMed]
- Rai, A.J.; Flores, R.M.; Mathew, A.; Gonzalez-Espinoza, R.; Bott, M.; Ladanyi, M.; Rusch, V.; Fleisher, M. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: Analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin. Chem. Lab. Med. 2010, 48, 271–278. [Google Scholar] [CrossRef] [PubMed]
- Kovac, V.; Dodic-Fikfak, M.; Arneric, N.; Dolzan, V.; Franko, A. Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma. Radiol. Oncol. 2015, 49, 279–285. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Ren, R.; Yin, P.; Zhang, Y.; Zhou, J.; Zhou, Y.; Xu, R.; Lin, H.; Huang, C. Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis. Oncotarget 2016, 7, 84851–84859. [Google Scholar] [CrossRef] [PubMed]
- Rapisarda, V.; Caltabiano, R.; Musumeci, G.; Castrogiovanni, P.; Ferrante, M.; Ledda, C.; Lombardo, C.; Graziano, A.C.E.; Cardile, V.; Loreto, C. Analysis of fibulin-3 after exposure to asbestos-like fibers. Environ. Res. 2017, 156, 381–387. [Google Scholar] [CrossRef] [PubMed]
- Pass, H.I.; Levin, S.M.; Harbut, M.R.; Melamed, J.; Chiriboga, L.; Donington, J.; Huflejt, M.; Carbone, M.; Chia, D.; Goodglick, L.; et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N. Engl. J. Med. 2012, 367, 1417–1427. [Google Scholar] [CrossRef] [PubMed]
- Creaney, J.; Dick, I.M.; Robinson, B.W. Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma. Curr. Opin. Pulm. Med. 2015, 21, 352–356. [Google Scholar] [CrossRef] [PubMed]
- Caltabiano, R.; Loreto, C.; Vitale, E.; Matera, S.; Miozzi, E.; Migliore, M.; Angelico, G.; Tumino, R.; Ledda, C.; Rapisarda, V. Fibulin-3 immunoexpression in malignant mesothelioma due to fluoro-edenite: A preliminary report. Future Oncol. 2018, 14, 53–57. [Google Scholar] [CrossRef] [PubMed]
- Shixian, M. Accuracy of fibulin-3 in the diagnosis of malignant pleural mesothelioma: A meta-analysis. Cancer Res. Clin. 2017, 29, 687–692. [Google Scholar]
- Pei, D.; Li, Y.; Liu, X.; Yan, S.; Guo, X.; Xu, X. Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis. Oncotarget 2017, 8, 13030–13038. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Creaney, J.; Dick, I.M.; Meniawy, T.M.; Leong, S.L.; Leon, J.S.; Demelker, Y.; Segal, A.; Musk, A.W.; Lee, Y.C.; Skates, S.J.; et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax 2014, 69, 895–902. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Kaya, H.; Demir, M.; Taylan, M.; Sezgi, C.; Tanrikulu, A.C.; Yilmaz, S.; Bayram, M.; Kaplan, I.; Senyigit, A. Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma. Asian Pac. J. Cancer Prev. 2015, 16, 1403–1407. [Google Scholar] [CrossRef] [PubMed]
- Battolla, E.; Canessa, P.A.; Ferro, P.; Franceschini, M.C.; Fontana, V.; Dessanti, P.; Pinelli, V.; Morabito, A.; Fedeli, F.; Pistillo, M.P.; et al. Comparison of the diagnostic performance of fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma. Anticancer Res. 2017, 37, 1387–1391. [Google Scholar] [PubMed]
- Kirschner, M.B.; Pulford, E.; Hoda, M.A.; Rozsas, A.; Griggs, K.; Cheng, Y.Y.; Edelman, J.J.; Kao, S.C.; Hyland, R.; Dong, Y.; et al. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br. J. Cancer 2015, 113, 963–969. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Rapisarda, V.; Ledda, C.; Migliore, M.; Salemi, R.; Musumeci, A.; Bracci, M.; Marconi, A.; Loreto, C.; Libra, M. FBLN-3 as a biomarker of pleural plaques in workers occupationally exposed to carcinogenic fibers: A pilot study. Future Oncol. 2015, 11, 35–37. [Google Scholar] [CrossRef] [PubMed]
- Tabata, C.; Shibata, E.; Tabata, R.; Kanemura, S.; Mikami, K.; Nogi, Y.; Masachika, E.; Nishizaki, T.; Nakano, T. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer 2013, 13, 205. [Google Scholar] [CrossRef] [PubMed]
- Napolitano, A.; Antoine, D.J.; Pellegrini, L.; Baumann, F.; Pagano, I.; Pastorino, S.; Goparaju, C.M.; Prokrym, K.; Canino, C.; Pass, H.I. HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin. Cancer Res. 2016, 22, 3087–3096. [Google Scholar] [CrossRef] [PubMed]
- Jube, S.; Rivera, Z.S.; Bianchi, M.E.; Powers, A.; Wang, E.; Pagano, I.; Pass, H.I.; Gaudino, G.; Carbone, M.; Yang, H. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012, 72, 3290–3301. [Google Scholar] [CrossRef] [PubMed]
- Rrapaj, E.; Trisolini, E.; Bertero, L.; Salvo, M.; Indellicato, R.; Andorno, S.; Garcia-Manteiga, J.M.; Rena, O.; Boldorini, R.L. Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma. Histopathology 2018, 72, 1039–1050. [Google Scholar] [CrossRef] [PubMed]
- Ying, S.; Jiang, Z.; He, X.; Yu, M.; Chen, R.; Chen, J.; Ru, G.; Chen, Y.; Chen, W.; Zhu, L.; et al. Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases. Dis. Markers 2017, 2017, 5756102. [Google Scholar] [CrossRef] [PubMed]
- Wu, T.; Zhang, W.; Yang, G.; Li, H.; Chen, Q.; Song, R.; Zhao, L. HMGB1 overexpression as a prognostic factor for survival in cancer: A meta-analysis and systematic review. Oncotarget 2016, 7, 50417–50427. [Google Scholar] [CrossRef] [PubMed]
- Jagirdar, R.; Solenov, E.I.; Hatzoglou, C.; Molyvdas, P.; Gourgoulianis, K.I.; Zarogiannis, S.G. Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma. Gene 2013, 517, 99–105. [Google Scholar] [CrossRef] [PubMed]
- Driml, J.; Pulford, E.; Moffat, D.; Karapetis, C.; Kao, S.; Griggs, K.; Henderson, D.W.; Klebe, S. Usefulness of aquaporin 1 as a prognostic marker in a prospective cohort of malignant mesotheliomas. Int. J. Mol. Sci. 2016, 17, 1041. [Google Scholar] [CrossRef] [PubMed]
- Benga, G. The first discovered water channel protein, later called aquaporin 1: Molecular characteristics, functions and medical implications. Mol. Asp. Med. 2012, 33, 518–534. [Google Scholar] [CrossRef] [PubMed]
- López-Campos, J.L.; Silva, S.R.; Izquierdo, G.L.; Márquez, E.; Ruiz, F.O.; Cejudo, P.; Barrot Cortés, E.; Toledo Aral, J.J.; Echevarría, M. Overexpression of aquaporin-1 in lung adenocarcinomas and pleural mesotheliomas. Histol. Histopathol. 2011, 26, 451–459. [Google Scholar] [PubMed]
- Kao, S.C.; Armstrong, N.; Condon, B.; Griggs, K.; McCaughan, B.; Maltby, S.; Wilson, A.; Henderson, D.W.; Klebe, S. Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma. Cancer 2012, 118, 2952–2961. [Google Scholar] [CrossRef] [PubMed]
- Klebe, S.; Griggs, K.; Cheng, Y.; Driml, J.; Henderson, D.W.; Reid, G. Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo model. Dis. Markers 2015, 2015, 286719. [Google Scholar] [CrossRef] [PubMed]
- Pulford, E.; McEvoy, J.; Hocking, A.; Prabhakaran, S.; Griggs, K.; Klebe, S. The effect of aquaporin 1-inhibition on vasculogenic mimicry in malignant mesothelioma. Int. J. Mol. Sci. 2017, 18, 2293. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.; Wu, L.; Ji, K.; Wang, W. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma. Tumor Biol. 2015, 36, 7375–7384. [Google Scholar] [CrossRef] [PubMed]
- Angelico, G.; Caltabiano, R.; Loreto, C.; Ieni, A.; Tuccari, G.; Ledda, C.; Rapisarda, V. Immunohistochemical expression of aquaporin-1 in fluoro-edenite-induced malignant mesothelioma: A preliminary report. Int. J. Mol. Sci. 2018, 19, 685. [Google Scholar] [CrossRef] [PubMed]
- Rapisarda, V.; Loreto, C.; Castorina, S.; Romano, G.; Garozzo, S.F.; Musumeci, A.; Migliore, M.; Avola, R.; Cinà, D.; Pomara, C.; Ledda, C. Occupational exposure to fluoro-edenite and prevalence of anti-nuclear autoantibodies. Future Oncol. 2018, 14, 59–62. [Google Scholar] [CrossRef] [PubMed]
- Rapisarda, V.; Rapisarda, G.; Vico, G.D.; Gobbi, L.; Loreto, C.; Valentino, M. Monitoring of fluoro-edenite fibre pollution through the study of sheep lymph nodes as a model of a biological indicator. Occup. Environ. Med. 2005, 62, 656. [Google Scholar] [CrossRef] [PubMed]
- Birnie, K.A.; Prêle, C.M.; Thompson, P.J.; Badrian, B.; Mutsaers, S.E. Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma. Oncotarget 2017, 8, 78193–78207. [Google Scholar] [CrossRef] [PubMed]
- Ledda, C.; Rapisarda, V. Malignant pleural mesothelioma: The need to move from research to clinical practice. Arch. Med. Res. 2016, 47, 407. [Google Scholar] [CrossRef] [PubMed]
- Truini, A.; Coco, S.; Nadal, E.; Genova, C.; Mora, M.; Dal Bello, M.G.; Vanni, I.; Alama, A.; Rijavec, E.; Biello, F.; et al. Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma. Oncotarget 2017, 8, 68627–68640. [Google Scholar] [CrossRef] [PubMed]
- Weber, D.G.; Johnen, G.; Bryk, O.; Jöckel, K.; Brüning, T. Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma—A pilot study. PLoS ONE 2012, 7, e30221. [Google Scholar] [CrossRef] [PubMed]
- Mairinger, F.D.; Werner, R.; Flom, E.; Schmeller, J.; Borchert, S.; Wessolly, M.; Wohlschlaeger, J.; Hager, T.; Mairinger, T.; Kollmeier, J.; et al. miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. Virchows Arch. 2017, 470, 627–637. [Google Scholar] [CrossRef] [PubMed]
- Gayosso-Gómez, L.V.; Zárraga-Granados, G.; Paredes-Garcia, P.; Falfán-Valencia, R.; Vazquez-Manríquez, M.E.; Martinez-Barrera, L.M.; Castillo-Gonzalez, P.; Rumbo-Nava, U.; Guevara-Gutierrez, R.; Rivera-Bravo, B.; et al. Identification of circulating miRNA profiles that distinguish malignant pleural mesothelioma from lung adenocarcinoma. EXCLI J. 2014, 13, 740–750. [Google Scholar] [PubMed]
- Cavalleri, T.; Angelici, L.; Favero, C.; DIoni, L.; Mensi, C.; Bareggi, C.; Alessandro, P.; Arianna, R.; Dario, C.; Lorenzo, B.; et al. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and Asbestos-Exposed subjects suggest a 2-miRNA signature as potential biomarker of disease. PLoS ONE 2017, 12, e0176680. [Google Scholar] [CrossRef] [PubMed]
- Lamberti, M.; Capasso, R.; Lombardi, A.; Di Domenico, M.; Fiorelli, A.; Feola, A.; Alessandra, F.P.; Mario, S.; Michele, C.; Diego, I. Two different serum MiRNA signatures correlate with the clinical outcome and histological subtype in pleural malignant mesothelioma patients. PLoS ONE 2015, 10, e0135331. [Google Scholar] [CrossRef] [PubMed]
- Belli, C.; Anand, S.; Tassi, G.; Fennell, D.; Mutti, L. Translational therapies for malignant pleural mesothelioma. Expert Rev. Respir. Med. 2010, 4, 249–260. [Google Scholar] [CrossRef] [PubMed]
- Balatti, V.; Maniero, S.; Ferracin, M.; Veronese, A.; Negrini, M.; Ferrocci, G.; Martini, F.; Tognon, M.G. MicroRNAs dysregulation in human malignant pleural mesothelioma. J. Thorac Oncol. 2011, 6, 844–851. [Google Scholar] [CrossRef] [PubMed]
- Mozzoni, P.; Ampollini, L.; Goldoni, M.; Alinovi, R.; Tiseo, M.; Gnetti, L.; Carbognani, P.; Rusca, M.; Mutti, A.; Percesepe, A.; et al. MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study. Dis. Markers 2017, 2017, 9645940. [Google Scholar] [CrossRef] [PubMed]
- De Santi, C.; Melaiu, O.; Bonotti, A.; Cascione, L.; Di Leva, G.; Foddis, R.; Cristaudo, A.; Lucchi, M.; Mora, M.; Truini, A.; et al. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Sci. Rep. 2017, 7, 3140. [Google Scholar] [CrossRef] [PubMed]
- Martínez-Rivera, V.; Negrete-García, M.C.; Ávila-Moreno, F.; Ortiz-Quintero, B. Secreted and tissue miRNAs as diagnosis biomarkers of malignant pleural mesothelioma. Int. J. Mol. Sci. 2018, 19, 595. [Google Scholar] [CrossRef] [PubMed]
Protein | Description | Analysis |
---|---|---|
Osteopontin | Encoded by the SPP1 gene (secreted phosphoprotein 1), which mediates cell-matrix interaction and cell signaling through interaction with integrin and CD44 receptors [44,45]. | Serum-Tissue |
Mesothelin | Encoded by the MSLN gene, that is expressed in mesothelial cells [51]. | Serum-Tissue |
Fibulin-3 | Encoded by the EFEMP1 gene (also known as S1-5) located on chromosome 2p16 [61,62,63]. | Serum-Bronchial Aspirates-Tissue |
HMGB1 | Encoded by the HMGB1 gene [74]. | Serum-Tissue |
Aquaporin-1 | Encoded by the AQP1 gene [81]. | Serum-Tissue |
mRNAs in MM | Clinical Utility | Sample Analysis |
---|---|---|
miRNA-126-3p | early diagnosis | Serum |
miRNA-625-3p | Serum | |
miRNA-103a-3p | Serum | |
miRNA-16-5p | Prognosis | Serum-Tissue |
miRNA-126-3p | Serum-Tissue | |
miRNA-143-3p | Serum-Tissue | |
miRNA-145-5p | Serum-Tissue | |
miRNA-192-5p | Serum-Tissue | |
miRNA-193a-3p | Serum-Tissue | |
miRNA-200b-3p | Serum-Tissue | |
miRNA-203a-3p | Serum-Tissue | |
miRNA-652-3p | Serum-Tissue |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ledda, C.; Senia, P.; Rapisarda, V. Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on. Cancers 2018, 10, 203. https://doi.org/10.3390/cancers10060203
Ledda C, Senia P, Rapisarda V. Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on. Cancers. 2018; 10(6):203. https://doi.org/10.3390/cancers10060203
Chicago/Turabian StyleLedda, Caterina, Paola Senia, and Venerando Rapisarda. 2018. "Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on" Cancers 10, no. 6: 203. https://doi.org/10.3390/cancers10060203